.Monopar Rehabs is bouncing back a drug coming from the scrap heap of AstraZeneca’s uncommon illness pipeline. It has actually licensed ALXN-1840, a prospect for
Read moreAZ lays out AI-enabled TROP2 biomarker tactic for Daiichi ADC
.AstraZeneca has actually made use of expert system to formulate a distinct biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), expecting to vary the
Read moreAN 2 halves headcount, ceases period 3 trial after information disappoint
.AN2 Therapeutics is actually reconsidering its service in feedback to lackluster midphase data, swearing to give up half its own employees as well as stop
Read moreALX’s fizzling CD47 response cost delivers stock spiraling down
.ALX Oncology’s period 2 gastric cancer reaction fee has compromised. After viewing its CD47 blocker quickly hammered command over the 1st half of the trial,
Read moreAC Immune sees ‘site’ prospective in Alzheimer’s medication information
.After much more than twenty years of focus on neurodegenerative health conditions, Swiss biotech AC Immune claims it could possibly have a video game changer
Read more